Search

Your search keyword '"GUASTALLA, JEAN-PAUL"' showing total 220 results
Start Over Author "GUASTALLA, JEAN-PAUL"
220 results on '"GUASTALLA, JEAN-PAUL"'

1. Impact of early palliative care on additional line of chemotherapy in metastatic breast cancer patients: results from the randomized study OSS

Author

Chvetzoff, Gisèle, Bouleuc, Carole, Lardy-Cléaud, Audrey, Saltel, Pierre, Dieras, Véronique, Morelle, Magali, Guastalla, Jean-Paul, Tredan, Olivier, Rebattu, Paul, Pop, Simona, Ray-Coquard, Isabelle, Pierga, Jean-Yves, Mignot, Laurent, Laurence, Valérie, Bourne-Branchu, Valérie, Pérol, David, and Bachelot, Thomas

Published
2023
Full Text
View/download PDF

2. Does a homeopathic medicine reduce hot flushes induced by adjuvant endocrine therapy in localized breast cancer patients? A multicenter randomized placebo-controlled phase III trial

Author

Heudel, Pierre-Etienne, Van Praagh-Doreau, Isabelle, Duvert, Bernard, Cauvin, Isabelle, Hardy-Bessard, Anne-Claire, Jacquin, Jean-Philippe, Stefani, Laetitia, Vincent, Lionel, Dramais, Dominique, Guastalla, Jean-Paul, Blanc, Ellen, Belleville, Aurélie, Lavergne, Emilie, and Pérol, David

Published
2019
Full Text
View/download PDF

4. Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study

Author

Diéras, Véronique, Wildiers, Hans, Jassem, Jacek, Dirix, Luc Y., Guastalla, Jean-Paul, Bono, Petri, Hurvitz, Sara A., Gonçalves, Anthony, Romieu, Gilles, Limentani, Steven A., Jerusalem, Guy, Lakshmaiah, K.C., Roché, Henri, Sánchez-Rovira, Pedro, Pienkowski, Tadeusz, Seguí Palmer, Miguel Ángel, Li, Ai, Sun, Yu-Nien, Pickett, Cheryl A., and Slamon, Dennis J.

Published
2015
Full Text
View/download PDF

5. Impact of early palliative care on additional line of chemotherapy in metastatic breast cancer patients: results from the randomized study OSS

Author

Chvetzoff, Gisèle, primary, Bouleuc, Carole, additional, Lardy-Cléaud, Audrey, additional, Saltel, Pierre, additional, Dieras, Véronique, additional, Morelle, Magali, additional, Guastalla, Jean-Paul, additional, Tredan, Olivier, additional, Rebattu, Paul, additional, Pop, Simona, additional, Ray-Coquard, Isabelle, additional, Pierga, Jean-Yves, additional, Mignot, Laurent, additional, Laurence, Valérie, additional, Bourne-Branchu, Valérie, additional, Pérol, David, additional, and Bachelot, Thomas, additional

Published
2022
Full Text
View/download PDF

6. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial

Author

Mackey, John R, Martin, Miguel, Pienkowski, Tadeusz, Rolski, Janusz, Guastalla, Jean-Paul, Sami, Amer, Glaspy, John, Juhos, Eva, Wardley, Andrew, Fornander, Tommy, Hainsworth, John, Coleman, Robert, Modiano, Manuel R, Vinholes, Jeferson, Pinter, Tamas, Rodríguez-Lescure, Álvaro, Colwell, Bruce, Whitlock, Pierre, Provencher, Louise, Laing, Kara, Walde, David, Price, Chris, Hugh, Judith C, Childs, Barrett H, Bassi, Kimberly, Lindsay, Mary-Ann, Wilson, Véronique, Rupin, Matthieu, Houé, Vincent, and Vogel, Charles

Published
2013
Full Text
View/download PDF

18. Adjuvant docetaxel for node-positive breast cancer

Author

Martin, Miguel, Juhos, Eva, Chap, Linnea, Al-Tweigeri, Taher, Tomiak, Eva, Weaver, Charles, Guastalla, Jean-Paul, Pawlicki, Marek, Mackey, John, Pienkowski, Tadeusz, Guevin, Raymond, Colwell, Bruce, Shou C.Tang, Pinter, Tamas, Modiano, Manuel, Vinholes, Jeferson, Coleman, Robert, Hainsworth, John, Fornander, Tommy, Howell, Anthony, Prady, Catherine, Loret, Camille, Judith, Hugh, Rodriguez-Lescure, Alvaro, Walde, David, Provencher, Louise, Rupin, Matthieu, Vogel, Charles, Riva Alessandro, Murawsky, Michael, Jacobs, Philips, and Blitz, Sandra

Subjects
Breast cancer -- Drug therapy, Cancer -- Adjuvant treatment, Cancer -- Health aspects
Abstract

A study was conducted in which comparison of docetaxel plus doxorubicin and cyclophosphamide (TAC) with fluorouracil plus doxorubicin and cyclophosphamide (FAC) is made as adjuvant chemotherapy for operable node-positive breast cancer. The result showed that adjuvant chemotherapy with TAC, as compared with FAC, significantly improves rates of disease-free and overall survival among women with operable node-positive breast cancer.

Published
2005

20. Traitements adjuvants du cancer du sein

Author

Guastalla, Jean-Paul, primary, Tredan, Olivier, additional, Ray-Coquard, Isabelle, additional, Labidi-Galy, Sana Intidhar, additional, Duret, Aude, additional, Cassier, Philippe, additional, and Bachelot, Thomas, additional

Published
2011
Full Text
View/download PDF

24. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors

Author

Tranchand, Brigitte, Catimel, Gilles, Lucas, Catherine, Sarkany, Marlis, Bastian, Gérard, Evene, Eric, Guastalla, Jean-Paul, Négrier, Sylvie, Rebattu, Paul, Dumortier, Arlette, Foy, Maurice, Grossin, François, Mazier, Béatrice, Froudarakis, Marios, Barbet, Nicolas, Clavel, Michel, and Ardiet, Claude

Published
1998
Full Text
View/download PDF

30. Disease-Free Survival Advantage of Weekly Epirubicin Plus Tamoxifen Versus Tamoxifen Alone As Adjuvant Treatment of Operable, Node-Positive, Elderly Breast Cancer Patients: 6-Year Follow-Up Results of the French Adjuvant Study Group 08 Trial

Author

Fargeot, Pierre, Bonneterre, Jacques, Roché, Henri, Lortholary, Alain, Campone, Mario, Van Praagh, Isabelle, Monnier, Alain, Namer, Moïse, Schraub, Simon, Barats, Jean-Claude, Guastalla, Jean-Paul, Goudier, Marie-Josèphe, and Chapelle-Marcillac, Isabelle

Published
2004
Full Text
View/download PDF

31. Adjuvant Use of Anastrozole in Breast Cancer

Author

Cuzick, Jack, Buzdar, Aman, Baum, Michael, Bianco, Raffaele, Coleman, Robert, Constenla, Manuel, Distler, Wolfgang, Dowsett, Mitch, Forbes, John, Guastalla, Jean Paul, Houghton, Joan, Williams, Norman, Howell, Anthony, Locker, Gershon, MacKey, John, Sainsbury, Richard, and Tobias, Jeffrey

Published
2004
Full Text
View/download PDF

34. Intensification of Adjuvant Chemotherapy: 5-Year Results of a Randomized Trial Comparing Conventional Doxorubicin and Cyclophosphamide With High-Dose Mitoxantrone and Cyclophosphamide With Filgrastim in Operable Breast Cancer With 10 or More Involved Axillary Nodes

Author

Fumoleau, Pierre, Chauvin, Franck, Namer, Moïse, Bugat, Roland, Tubiana-Hulin, Michèle, Guastalla, Jean Paul, Delozier, Thierry, Kerbrat, Pierre, Devaux, Yves, Bonneterre, Jacques, Filleul, Annie, and Clavel, Michel

Published
2001

36. Can treatment with Cocculine improve the control of chemotherapy-induced emesis in early breast cancer patients? A randomized, multi-centered, double-blind, placebo-controlled Phase III trial

Author

Pérol David, Provençal Jocelyne, Hardy-Bessard Anne-claire, Coeffic David, Jacquin Jean-Phillipe, Agostini Cécile, Bachelot Thomas, Guastalla Jean-Paul, Pivot Xavier, Martin Jean-Pierre, Bajard Agathe, and Ray-Coquard Isabelle

Subjects
Early breast cancer, Adjuvant chemotherapy, Homeopathy, Nausea and vomiting, Quality of life, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Chemotherapy induced nausea and vomiting (CINV) remains a major problem that seriously impairs the quality of life (QoL) in cancer patients receiving chemotherapy regimens. Complementary medicines, including homeopathy, are used by many patients with cancer, usually alongside with conventional treatment. A randomized, placebo-controlled Phase III study was conducted to evaluate the efficacy of a complex homeopathic medicine, Cocculine, in the control of CINV in non-metastatic breast cancer patients treated by standard chemotherapy regimens. Methods Chemotherapy-naïve patients with non-metastatic breast cancer scheduled to receive 6 cycles of chemotherapy including at least three initial cycles of FAC 50, FEC 100 or TAC were randomized to receive standard anti-emetic treatment plus either a complex homeopathic remedy (Cocculine, registered in France for treatment of nausea and travel sickness) or the matching placebo (NCT00409071 clinicaltrials.gov). The primary endpoint was nausea score measured after the 1st chemotherapy course using the FLIE questionnaire (Functional Living Index for Emesis) with 5-day recall. Secondary endpoints were: vomiting measured by the FLIE score, nausea and vomiting measured by patient self-evaluation (EVA) and investigator recording (NCI-CTC AE V3.0) and treatment compliance. Results From September 2005 to January 2008, 431 patients were randomized: 214 to Cocculine (C) and 217 to placebo (P). Patient characteristics were well-balanced between the 2 arms. Overall, compliance to study treatments was excellent and similar between the 2 arms. A total of 205 patients (50.9%; 103 patients in the placebo and 102 in the homeopathy arms) had nausea FLIE scores > 6 indicative of no impact of nausea on quality of life during the 1st chemotherapy course. There was no difference between the 2 arms when primary endpoint analysis was performed by chemotherapy stratum; or in the subgroup of patients with susceptibility to nausea and vomiting before inclusion. In addition, nausea, vomiting and global emesis FLIE scores were not statistically different at any time between the two study arms. The frequencies of severe (Grade ≥ 2) nausea and vomiting were low in our study (nausea: P: 17.6% vs C: 15.7%, p=0.62; vomiting: P: 10.8% vs C: 12.0%, p=0.72 during the first course). Conclusion This double-blinded, placebo-controlled, randomised Phase III study showed that adding a complex homeopathic medicine (Cocculine) to standard anti-emetic prophylaxis does not improve the control of CINV in early breast cancer patients.

Published
2012
Full Text
View/download PDF

39. Does a homeopathic medicine reduce hot flushes induced by adjuvant endocrine therapy in localized breast cancer patients? A multicenter randomized placebo-controlled phase III trial

Author

Heudel, Pierre-Etienne, primary, Van Praagh-Doreau, Isabelle, additional, Duvert, Bernard, additional, Cauvin, Isabelle, additional, Hardy-Bessard, Anne-Claire, additional, Jacquin, Jean-Philippe, additional, Stefani, Laetitia, additional, Vincent, Lionel, additional, Dramais, Dominique, additional, Guastalla, Jean-Paul, additional, Blanc, Ellen, additional, Belleville, Aurélie, additional, Lavergne, Emilie, additional, and Pérol, David, additional

Published
2018
Full Text
View/download PDF

40. Can a homeopathic medicine complex reduce hot flashes induced by adjuvant endocrine therapy in localized breast cancer patients? Results of a randomized placebo-controlled phase III trial.

Author

Heudel, Pierre-Etienne, primary, Van Praagh, Isabelle, additional, Duvert, Bernard, additional, Cauvin, Isabelle, additional, Hardy-Bessard, Anne-Claire, additional, Jacquin, Jean-Philippe, additional, Stefani, Laetitia, additional, Belliere, Aurelie, additional, Vincent, Lionel, additional, Dramais, Dominique, additional, Guastalla, Jean-Paul, additional, Blanc, Ellen, additional, Belleville, Aurelie, additional, Lavergne, Emilie, additional, and Pérol, David, additional

Published
2015
Full Text
View/download PDF

41. [Prognostic factors for febrile neutropenia]

Author

Ray-Coquard, Isabelle, Borg, Christophe, Bachelot, Thomas, Fayette, Jerome, Zufferey, Laura, Guastalla, Jean-Paul, Ghesquiere, Herve, Jean-Yves Blay, Sebban, Catherine, Marec-Berard, Perrine, Biron, Pierre, Centre Léon Bérard [Lyon], Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), and Saas, Philippe

Subjects
MESH: Humans, Neutropenia, MESH: Neutropenia, Fever, MESH: Disease Susceptibility, [SDV.CAN]Life Sciences [q-bio]/Cancer, Antineoplastic Agents, Antibiotic Prophylaxis, Hematopoietic Cell Growth Factors, Prognosis, MESH: Hematinics, MESH: Prognosis, Recombinant Proteins, [SDV.CAN] Life Sciences [q-bio]/Cancer, MESH: Antibiotic Prophylaxis, MESH: Fever, Granulocyte Colony-Stimulating Factor, Hematinics, MESH: Antineoplastic Agents, Humans, Disease Susceptibility, MESH: Granulocyte Colony Stimulating Factor, Recombinant, MESH: Hematopoietic Cell Growth Factors
Abstract

International audience; Cytotoxic chemotherapy suppresses the haematopoietic system, impairing host protective mechanisms and limiting the doses of chemotherapy that can be tolerated. Febrile neutropenia, the most serious haematological toxicity, is associated with the risk of life-threatening infections as well as chemotherapy dose reductions and delays that may compromise treatment outcomes. The recent literature in chemotherapy-induced neutropenia and its complications and impact was provided an update on research, and the implications for improving the management of patients with cancer who are treated with myelosuppressive chemotherapy was discussed. Despite its importance as the primary dose-limiting toxicity of chemotherapy, much concerning neutropenia and its consequences and impact remains unknown. Recent surveys indicate that neutropenia remains a prevalent problem associated with substantial morbidity, mortality, and costs. The colony-stimulating factors (CSFs) have been used effectively in a variety of clinical settings to prevent or treat febrile neutropenia and to assist patients receiving dose-intensive chemotherapy. A meta-analysis of the available randomized controlled trials (RCTs) has confirmed the efficacy of prophylactic CSFs. Much research has sought to identify risk factors that may predispose patients to neutropenic complications, including febrile neutropenia, in an effort to predict better which patients are at risk and to use preventive strategies, such as prophylactic colony-stimulating factors, more cost-effectively. Research in quantifying the risk of neutropenic complications may make it possible in the near future to target patients at greater risk with appropriate preventive strategies, thereby maximizing the benefits and minimizing the costs.

Published
2004

42. [Standards, Options and Recommendations 2000: non metastatic endometrial cancer]

Author

Alain, Brémond, Anne, Bataillard, Laurence, Thomas, Jean-Louis, Achard, Béatrice, Fervers, Eric, Fondrinier, Jacques, Lansac, Corinne, Bailly, Sylvette, Hoffstetter, Joëlle, d'Anjou, Philipee, Descamps, Fadila, Farsi, Guastalla, Jean-Paul, François, Laffargue, Jean-François, Rodier, Pascal, Vincent, and Jacques, Pigneux

Subjects
Humans, Lymph Node Excision, Female, Prognosis, Neoadjuvant Therapy, Endometrial Neoplasms, Neoplasm Staging, Pelvis
Abstract

The "Standards, Options and Recommendations" (SOR) project, started in 1993, is a collaboration between the Federation of French Cancer Centers (FNCLCC), the 20 French Cancer Centers, and specialists from French Public Universities, General Hospitals and Private Clinics, and some specialists learned societies. The main objective is the development of clinical practice guidelines to improve the quality of health care and the outcome of cancer patients. The SORs are developed using a methodology based on a literature review and critical appraisal by a multidisciplinary group of experts, with feedback from specialists in cancer care delivery.To develop clinical practice guidelines for the management of patients with carcinoma of the endometrium according to the definitions of the Standards, Options and Recommendations project.Data were identified by searching Medline , web sites, and using the personal reference lists of members of the expert groups. Once the guidelines were defined, the document was submitted for review to 63 independent reviewers.The main recommendations for the management of carcinoma of the endometrium are: 1) The diagnosis of carcinoma of the endometrium is based on biopsy and histological examination. However, as first intention, the first elements for diagnosis can be obtain from a hysterography, or particularly, a endovaginal ultrasound examination. Ultrasound allows locoregional metastases to be detected, the CT scan allows the lymph node involvement to be assessed and magnetic resonance imaging allows the myometrium invasion to be evaluated. 2) For the majority of patients, surgery is the initial treatment, both for localised and advanced-stage carcinomas. The excised sample can be used for pathological analysis and tumour staging, using the FIGO (Fédération internationale de gynécologie obstétrique) classification. Surgery for patients with stage I and II carcinomas involves total extrafascial hysterectomy with bilateral salpingo-oophorectomy., In patients with stage III and IV carcinomas radical surgery should be performed, when possible. If this is not possible, then surgery should be as complete as possible and be associated with a complementary treatment. In patients with the most advanced carcinomas, tumour reduction by surgery should be performed. 3) Complementary treatment includes external-beam radiotherapy and brachytherapy. The decision concerning the extent and type of irradiation should be taken taking into consideration the stage and the prognostic factors present. For patients with stage I and II carcinoma, complementary treatment with brachytherapy can be performed, if the myometrium invasion is not deep, or if the carcinoma is grade 2 or 3. Patients with stage III carcinomas can be treated with pelvic or abdominal-pelvic complementary irradiation. In patients that cannot undergo surgery, exclusive radiotherapy can be performed. 4) In the absence of any symptoms, surveillance should include a general clinical and gynaecological examination. All patients with symptoms should undergo an additional work-up.

Published
2002

43. Impact of the trifunctional antibody catumaxomab followed by systemic chemotherapy (CTX) on overall survival (OS): Results of a subgroup analysis in patients (pts) with relapsed ovarian cancer (OC) and malignant ascites (MA).

Author

Chekerov, Radoslav, primary, Wimberger, Pauline, additional, Vergote, Ignace, additional, Rosenberg, Per, additional, Schneeweiss, Andreas, additional, Scambia, Giovanni, additional, Guastalla, Jean Paul, additional, Colombo, Nicoletta, additional, Westermann, A.M., additional, Lordick, Florian, additional, Schulze, Elisabeth, additional, and Sehouli, Jalid, additional

Published
2013
Full Text
View/download PDF

44. Catumaxomab with and without prednisolone in patients with malignant ascites due to epithelial cancer: Results from the phase IIIb CASIMAS study.

Author

Sehouli, Jalid, primary, Wimberger, Pauline, additional, Vergote, Ignace B., additional, Rosenberg, Per, additional, Schneeweiss, Andreas, additional, Bokemeyer, Carsten, additional, Salat, Christoph, additional, Scambia, Giovanni, additional, Berton-Rigaud, Dominique, additional, Siena, Salvatore, additional, Santoro, Armando, additional, Cervantes-Ruiperez, Andres, additional, Guastalla, Jean Paul, additional, Tournigand, Christophe, additional, Colombo, Nicoletta, additional, Dudnitchenko, Alexander Serg, additional, Bondar, Vladimir, additional, Westermann, A.M., additional, and Lordick, Florian, additional

Published
2012
Full Text
View/download PDF

45. Quality of life in patients with malignant ascites during catumaxomab treatment: Results from the CASIMAS trial.

Author

Lordick, Florian, primary, Sehouli, Jalid, additional, Vergote, Ignace B., additional, Rosenberg, Per, additional, Schneeweiss, Andreas, additional, Block, Andreas, additional, Salat, Christoph, additional, Scambia, Giovanni, additional, Berton-Rigaud, Dominique, additional, Siena, Salvatore, additional, Santoro, Armando, additional, Cervantes-Ruiperez, Andres, additional, Guastalla, Jean Paul, additional, Tournigand, Christophe, additional, Colombo, Nicoletta, additional, Dudnitchenko, Alexander Serg, additional, Bondar, Vladimir, additional, Westermann, A.M., additional, Gonschior, Ann-Katrin, additional, and Wimberger, Pauline, additional

Published
2012
Full Text
View/download PDF

46. Traitements adjuvants dans le cancer du sein : impact du résultat du curage axillaire en cas de micrométastase ou de cellules tumorales isolées dans le ganglion sentinelle

Author

Schmitt, Caroline, primary, Bouteille, Catherine, additional, Faure, Christelle, additional, Mignotte, Hervé, additional, Tredan, Olivier, additional, Bachelot, Thomas, additional, Guastalla, Jean-Paul, additional, Arnaud, Antoine, additional, Treilleux, Isabelle, additional, and Carrabin, Nicolas, additional

Published
2012
Full Text
View/download PDF

47. Multidisciplinarity and medical decision, impact for patients with cancer: sociological assessment of two tumour committees’ organization

Author

Castel, Patrick, primary, Tassy, Louis, additional, Lurkin, Antoine, additional, Blay, Jean-Yves, additional, Meeus, Pierre, additional, Mignotte, Herve, additional, Faure, Christelle, additional, Ranchere-Vince, Dominique, additional, Bachelot, Thomas, additional, Guastalla, Jean-Paul, additional, Sunyach, Marie-Pierre, additional, Guerin, Nicole, additional, Treilleux, Isabelle, additional, Marec-Berard, Perrine, additional, Thiesse, Philippe, additional, and Ray-Coquard, Isabelle, additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results